

Clinical Trial Protocol

Iranian Registry of Clinical Trials

19 Sep 2026

A comparison of Topical T3 Hormone and placebo in treatment of patients with Alopecia Areata

Protocol summary

Summary

A randomized double blind placebo controlled clinical trial study is designed to evaluate the effect of topical T3 hormone on Alopecia Areata. This study will be performed by collaboration of skin Research center of shahid Beheshti Medical University and Endocrine and Metabolism research Institute of Tehran Medical University. This is a phase II clinical trial. 10 patients with at least two patches of alopecia areata on 2 different sides of body will be recruited. Complete history will be taken and patients with clinical and para clinical signs and symptoms of thyroid disease will be excluded from study. The size of the alopecia patch will be measured before therapy. T3 cream is composed of 3.8 microgram of T3 in each 30 microgram of novasome A. Novasome A will be used as placebo. The patient will apply T3 hormone on one side and placebo on the other side for 12 weeks. The size of the patch, the hair count, hair type (velus or terminal) and hair color (white or black) will be determined every 4 weeks. Thyroid function test, Liver function test and CBC will be performed before the start and at the end of therapy. At the beginning of the study and every 4 weeks a photograph will be taken from the lesions.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138902141414N14**

Registration date: **2010-05-28, 1389/03/07**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2010-05-28, 1389/03/07

Registrant information

Name

Bagher Larijani

Name of organization / entity

Endocrinology & Metabolism Research Center, Tehran
University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8822 0037

Email address

emrc@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Endocrinology and Metabolism Research Institute of
Tehran university of medical sciences

Expected recruitment start date

2009-04-01, 1388/01/12

Expected recruitment end date

2011-01-01, 1389/10/11

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A comparison of Topical T3 Hormone and placebo in
treatment of patients with Alopecia Areata

Public title

Topical T3 Hormone effect in alopecia areata

Purpose

Treatment

Inclusion/Exclusion criteria

exclusion criteria: 1. clinical or paraclinical evidence of
thyroid dysfunction (hypo or hyperthyroidism) 2.
paraclinical data confirming abnormality of CBC,LFT 3.

patients with Alopecia Totalis or universalis. inclusion:
Patients with at least 2 patches of alopecia on 2 different
side of body

Age

No age limit

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: 10

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Endocrinology and Metabolism research institute of
Tehran Medical University

Street address

Shariati Hospital.North Karegar Ave.

City

Tehran

Postal code**Approval date**

2009-03-01, 1387/12/11

Ethics committee reference number

E-0087

Health conditions studied**1****Description of health condition studied**

Alopecia Areata

ICD-10 code

L63

ICD-10 code description

Alopecia areata

Primary outcomes**1****Description**

Hair regrowth

Timepoint

At the begining, every four weeks and at the end

Method of measurement

Observation and photography

Secondary outcomes**1****Description**

Hair color

Timepoint

at the begining, every4 weeks and at the end

Method of measurement

observation

Intervention groups**1****Description**

Topical T3 cream, 3.8 microgram of T3 in each 30
microgram of novasome A, two times daily for 12 weeks.
The patient will apply T3 hormone on one side and
placebo on the other side.

Category

Treatment - Drugs

2**Description**

Novasome A will be used as placebo and applied in the
same way as the intervention group on the other side

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Shohada-e-Tajrish Hospital.

Full name of responsible person

Marjan Saeedi

Street address

Shahrdari Ave,Shohada-e-Tajrish Hospital.

City

Tehran

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Endocrinology and Metabolism Research Institute of
Tehran University of Medical Sciences

Full name of responsible person

Ramin Heshmat

Street address

Shariati Hospital, North Karegar Ave.

City

Tehran

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding sourceEndocrinology and Metabolism Research Institute of
Tehran University of Medical Sciences**Proportion provided by this source**

100

Public or private sector*empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Person responsible for scientific inquiries****Contact****Name of organization / entity**Endocrinology and Metabolism Research Institute of
Tehran university of medical sciences**Full name of responsible person**

Bagher Larijani

Position

MD

Other areas of specialty/work**Street address**

Shariati Hospital, North Kargar Ave

City

Tehran

Postal code**Phone**

+98 21 8822 0037

Fax**Email**

emrc@tums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**skin Reserch center of shahid Beheshti Medical
university**Full name of responsible person**

Marjan Saeedi

Position

MD

Other areas of specialty/work**Street address**

Shohada-e-Tajrish Hospital, Shahr-dari Ave

City

Tehran

Postal code**Phone**

+98 912 216 6322

Fax**Email**

marjan406@yahoo.com; msaeedi1360@gmail.com

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*